ACCOUNTS - Final Accounts


Caseware UK (AP4) 2019.0.227 2019.0.227 2020-02-292020-02-292020-05-11falseThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false2019-03-01No description of principal activitytrue 10018044 2019-03-01 2020-02-29 10018044 2020-02-29 10018044 2019-02-28 10018044 c:Director1 2019-03-01 2020-02-29 10018044 d:CurrentFinancialInstruments 2020-02-29 10018044 d:CurrentFinancialInstruments 2019-02-28 10018044 d:CurrentFinancialInstruments d:WithinOneYear 2020-02-29 10018044 d:CurrentFinancialInstruments d:WithinOneYear 2019-02-28 10018044 d:Non-currentFinancialInstruments d:AfterOneYear 2020-02-29 10018044 d:Non-currentFinancialInstruments d:AfterOneYear 2019-02-28 10018044 d:ShareCapital 2020-02-29 10018044 d:ShareCapital 2019-02-28 10018044 d:RetainedEarningsAccumulatedLosses 2020-02-29 10018044 d:RetainedEarningsAccumulatedLosses 2019-02-28 10018044 c:FRS102 2019-03-01 2020-02-29 10018044 c:AuditExempt-NoAccountantsReport 2019-03-01 2020-02-29 10018044 c:FullAccounts 2019-03-01 2020-02-29 10018044 c:PrivateLimitedCompanyLtd 2019-03-01 2020-02-29 iso4217:GBP

Registered number: 10018044









TOXICOLOGY UK LTD







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 29 FEBRUARY 2020

 
TOXICOLOGY UK LTD
REGISTERED NUMBER: 10018044

BALANCE SHEET
AS AT 29 FEBRUARY 2020

29 February
28 February
2020
2019
Note
£
£

  

Current assets
  

Debtors: amounts falling due within one year
 4 
-
57,488

Cash at bank and in hand
  
50,035
69,575

  
50,035
127,063

Creditors: amounts falling due within one year
 5 
(10,915)
(142,492)

Net current assets/(liabilities)
  
 
 
39,120
 
 
(15,429)

Total assets less current liabilities
  
39,120
(15,429)

Creditors: amounts falling due after more than one year
  
(5,076)
-

  

Net assets/(liabilities)
  
34,044
(15,429)


Capital and reserves
  

Called up share capital 
  
1
1

Profit and loss account
  
34,043
(15,430)

  
34,044
(15,429)


The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 11 May 2020.

................................................
Dr S Elliott
Page 1

 
TOXICOLOGY UK LTD
REGISTERED NUMBER: 10018044
    
BALANCE SHEET (CONTINUED)
AS AT 29 FEBRUARY 2020

Director

The notes on pages 3 to 5 form part of these financial statements.

Page 2

 
TOXICOLOGY UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 FEBRUARY 2020

1.


General information

Toxicology UK Limited is a private company limited by shares, incorporated in England & Wales and domiciled in England.
The registered office of the company is 45 Church Street, Birmingham, B3 2RT.
2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The financial statements are presented in pound sterling, which is considered to be the company's funcional currency and are rounded to the nearest £1.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

Page 3

 
TOXICOLOGY UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 FEBRUARY 2020

2.Accounting policies (continued)

 
2.3

Taxation

Tax is recognised in the Statement of Comprehensive Income, except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

 
2.4

Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.5

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.6

Creditors

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.7

Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of Comprehensive Income.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate of the recoverable amount, which is an approximation of the amount that the Company would receive for the asset if it were to be sold at the balance sheet date.

Page 4

 
TOXICOLOGY UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 FEBRUARY 2020

2.Accounting policies (continued)

 
2.8

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 0 (2019 - 0).


4.


Debtors

29 February
28 February
2020
2019
£
£


Prepayments and accrued income
-
57,488

-
57,488



5.


Creditors: Amounts falling due within one year

29 February
28 February
2020
2019
£
£

Corporation tax
8,949
-

Other taxation and social security
17
2,356

Other creditors
(1)
26,912

Accruals and deferred income
1,950
113,224

10,915
142,492



6.


Controlling party

The controlling party of the company is considered to be Simon Elliot due to his 100% owning of share capital.

 
Page 5